Avalo Enhances Change-in-Control Terms for All Four C-Suite Executives
Coc Protection Update
Company Background
Avalo Therapeutics is a clinical-stage biotech company developing IL-1β inhibitors for immune-mediated inflammatory diseases. Its lead asset, abdakibart (AVTX-009), met the primary endpoint of its Phase 2 LOTUS trial on May 5, 2026, showing HiSCR75 response rates of 42.2% and 42.9% at the two dose levels versus 25.6% for placebo in 253 adults with moderate to severe hidradenitis suppurativa. The company plans to advance the drug into a registrational Phase 3 program.
Immediately following the data readout, Avalo completed a public equity offering on May 7, 2026, raising approximately $405 million in net proceeds. Combined with $82 million already on hand as of March 31, 2026, management estimated the combined cash position would fund operations into 2029. The company has no product revenue to speak of — full-year 2025 net product revenue was $59,000 — and reported a net loss of $78.3 million for 2025, up from $35.1 million the prior year, driven primarily by Phase 2 trial costs.
What Was Disclosed
On June 12, 2026, Avalo amended employment agreements with CEO Garry Neil, CFO Christopher Sullivan, CMO Mittie Doyle, and Chief Business Officer Taylor Boyd to add or enhance severance and change-in-control protections. In the event of a termination without cause or for good reason outside a change-in-control window, each executive is entitled to 12 months of base salary in substantially equal installments — 18 months for Neil — plus payment of any prior-year unpaid bonus, a prorated current-year bonus, and company-paid COBRA premiums. Options granted before June 12, 2026 vest in full on such a termination.
In a change-in-control context — defined as a qualifying termination in the window beginning three months before and ending 12 months after a change in control — the cash severance steps up. Neil would receive 1.5 times base salary plus 1.0 times target annual bonus; Sullivan, Doyle, and Boyd each receive 1.0 times base salary plus 1.0 times target bonus. All outstanding and unvested time-based equity awards accelerate in full. Additionally, even without a termination, all time-based equity held by these executives vests on the first anniversary of a change in control, provided the executive remains employed through that date. Payments are subject to a 280G cap with no excise-tax gross-up: if the aggregate payments would trigger the Section 4999 excise tax, they are reduced to $1 below the applicable threshold, but only if the reduction results in a higher after-tax amount for the executive.
On June 11, 2026, the day before the employment amendments, the company filed a Certificate of Designation with the Delaware Secretary of State creating the Series C-1 Preferred Stock. The filing states explicitly that the sole purpose was to allow an existing accredited investor to exchange 4,294.675 shares of Series C Preferred Stock for an identical Series C-1 class — the only difference being the removal of a restriction that had previously prevented that investor from raising its beneficial ownership conversion cap from 4.99% to 9.99% of common stock. The exchange is not a new investment; it creates no new capital. Upon closing, 4,085.379 shares of the original Series C remain outstanding.
Why It Matters
The compensation amendments arrive at a specific moment in the company's lifecycle: five weeks after its first major clinical success and the close of a large financing that gives Avalo a balance sheet uncommon for a pre-revenue biotech. Well-capitalized companies with validated assets are often acquisition targets, and change-in-control protection packages are standard preparation for that scenario. That said, they are equally standard retention tools adopted after a major value-creating event — the amendments could simply reflect the board's view that it needed to strengthen its hand to retain key personnel as Avalo moves toward a multi-year Phase 3 program. The filings do not disclose which motivation applies.
The Series C-1 exchange was initially flagged as a potential deal signal, but the text of the filing removes that ambiguity. An existing holder — already owning Series C shares — asked to have the 4.99% conversion floor lifted so it could convert up to 9.99% at a time of its choosing. This is a routine accommodation that does not imply a new strategic relationship or transaction.
One structural feature of the employment amendments merits attention: the "modified single-trigger" equity acceleration clause. All time-based equity held by the four executives will vest automatically on the first anniversary of any change in control even if they are not terminated, as long as they remain employed. In a traditional double-trigger structure, acceleration only occurs upon termination. The modified single-trigger element means that in an acquisition, the acquirer is effectively guaranteed to see these executives' unvested equity convert to cost on a defined schedule, regardless of whether the executives leave. That is a non-trivial negotiating dynamic in any deal discussions, though the filing does not indicate any transaction is underway.
